Announcements
- Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
- Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
- European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivot
- Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
- Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023
- Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
- Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
- Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering
- Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results
- Scinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Boston
More ▼
Key statistics
On Friday, Scinai Immunotherapeutics Ltd (2F5:FRA) closed at 3.68, 19.91% above the 52 week low of 3.07 set on Jun 05, 2024.
52-week range
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | 3.02 |
Offer | 3.42 |
Previous close | 3.68 |
Average volume | 0.00 |
---|---|
Shares outstanding | 150.00 |
Free float | -- |
P/E (TTM) | -- |
Market cap | 2.03m USD |
EPS (TTM) | -231.24 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 08:59 BST.
More ▼